Beta-agonists Dopamine Dopamine is an endogenous catecholamine that exerts its dose-dependent effects on the cardiovascular system via its interaction with four different receptors: dopaminergic type 1 and type 2 and adrenergic alpha-1 and beta When used at lower doses of up to 2. While theoretically this effect seems favourable for the renal function of AHF patients, as it increases renal perfusion, there is no evidence that this translates to significant clinical benefit. In a cohort of patients in intensive care with impending renal failure, the administration of low-dose IV dopamine did not prove to have any benefit in terms of reduction of peak creatinine levels or prevention of worsening renal function compared with placebo. This leads to a significantly elevated afterload that can prove detrimental for patients with AHF and systolic dysfunction. It also affects the peripheral vasculature due to its combined action on vascular alpha-1 receptors and beta-2 receptors.
|Published (Last):||8 February 2010|
|PDF File Size:||4.38 Mb|
|ePub File Size:||12.45 Mb|
|Price:||Free* [*Free Regsitration Required]|
Beta-agonists Dopamine Dopamine is an endogenous catecholamine that exerts its dose-dependent effects on the cardiovascular system via its interaction with four different receptors: dopaminergic type 1 and type 2 and adrenergic alpha-1 and beta When used at lower doses of up to 2. While theoretically this effect seems favourable for the renal function of AHF patients, as it increases renal perfusion, there is no evidence that this translates to significant clinical benefit.
In a cohort of patients in intensive care with impending renal failure, the administration of low-dose IV dopamine did not prove to have any benefit in terms of reduction of peak creatinine levels or prevention of worsening renal function compared with placebo. This leads to a significantly elevated afterload that can prove detrimental for patients with AHF and systolic dysfunction.
It also affects the peripheral vasculature due to its combined action on vascular alpha-1 receptors and beta-2 receptors. However, several studies have linked its use with an increase in mortality rates.
One meta-analysis showed that dobutamine was associated with higher risk of in-hospital mortality and future HF readmissions compared with the vasodilator nesiritide. When prescribing dobutamine, it should be noted that the effect of dobutamine may be blunted in patients who are under chronic beta-blockade therapy, at least in usual doses.
Another important limitation of dobutamine is that tolerance may develop even after short administration periods. It also acts on cardiac beta-1 receptors, thereby exerting chronotropic and inotropic effects.
Based on these properties, norepinephrine is primarily used in patients with AHF who present with cardiogenic shock, always in addition to another more potent inotropic agent. Norepinephrine is also used in combination with inodilators to prevent the development of hypotension. Even though no statistically significant difference was found between the two arms in terms of mortality, dopamine was associated with an increased risk for adverse events including arrhythmias compared with norepinephrine.
Notably, a subgroup analysis from the same trial including only patients with cardiogenic shock showed that norepinephrine was superior to dopamine in terms of reduction in mortality. Adverse events of norepinephrine include tachycardia that can significantly increase myocardial oxygen demand, which may be detrimental, especially in cases of active myocardial ischaemia.
Also, it has been documented that norepinephrine has a direct toxic effect on cardiac cells, primarily due to cell apoptosis induced by beta adrenergic stimulation. Epinephrine Epinephrine, also an endogenous catecholamine, exhibits dose-dependent effects. When administered at lower doses of up to 0. This vasoconstriction includes not only the peripheral vasculature but also pulmonary arterial and venous circulation. Despite its inotropic, chronotropic and vasoconstrictive properties, epinephrine has been limited in everyday clinical practice to cases of cardiac arrest.
This is due to the results from a pilot study by Levy et al. It was found that epinephrine use in patients with cardiogenic shock was associated independently with increased day mortality and with declining renal and cardiac function. Notable adverse effects of epinephrine include myocardial ischaemia, arrhythmias, hypertension, pulmonary congestion and intracranial bleeding.
Through this inhibition, cAMP accumulates in the cell, causing protein kinase A activation. This facilitates more calcium ions to enter the myocardial cell, thus potentiating the actin-myosin cross-bridging leading to increased cardiac contractility. This mechanism is independent of the beta-adrenergic pathway. As a result, the use of PDE3 inhibitors, and milrinone in particular, is suitable for patients with chronic HF under beta-blockade who present with AHF or cardiogenic shock compared with other inotropes.
The short- and long-term effects of milrinone have been investigated. No statistically significant benefit was found from the use of milrinone in terms of mortality or hospitalisations, whereas milrinone was linked to increased risk of prolonged hypotensive episodes and arrhythmias.
For patients with systolic blood pressure in the lower range 85— mmHg , milrinone is recommended to be used in combination with a vasoconstrictor, such as norepinephrine, to counteract its vasodilating effect.
In addition, milrinone is preferred in patients who chronically receive beta-blockers, due to its beta-adrenergic pathway which is an independent mechanism of action. Hypotension and tachyarrhythmias are also documented adverse effects of milrinone. As its effects are not a result of influx of calcium in the myocyte, its arrhythmogenic potential is significantly limited.
In addition to its positive inotropic effect, levosimendan leads to peripheral vasodilation via the opening of ATP-sensitive potassium channels on smooth muscle cells of the vasculature.
Initial levosimendan studies showed promising results, despite their limited size. Current European Society of Cardiology guidelines reserve its use in AHF patients with hypoperfusion that may be related to beta-blockade therapy. Adverse effects include hypotension, AF, hypokalemia, headache and arrhythmias.
Novel Inotropic Agents Omecamtiv Mecarbil Omecamtiv mecarbil OM is the first and most investigated agent in a new class of inotropes called cardiac myosin activators. This leads to a stabilisation of the lever arm of myosin, rendering it primed. This effect when multiplied for numerous intracellular myosin molecules prior to the initiation of contraction, produces an increased number of primed myosin molecules and consequently an increased number of myosin heads available to cross-bridge with actin generating increased contractile force.
Additionally, since OM acts independently of the adrenergic pathway, it can be used as an alternative to milrinone and levosimendan in HF patients who are taking beta-blockers.
Specifically, when compared to placebo, OM increased stroke volume and ejection fraction in AHF patients. This has been hypothesised to be a result of diminished coronary filling during diastole due to prolonged ventricular systolic phase. The mechanism for the increases in troponin at therapeutically relevant exposures is currently unknown. SERCA2a, via this mechanism, affects the mechanics of both diastole and systole and its expression is long known to be reduced in HF patients, leading to systolic impairment.
This gene therapy strategy initially proved to have an acceptable safety profile in and was tested in terms of efficacy in phase II trials. It was documented that gene delivery was superior to placebo in terms of symptomatic improvement, exercise tolerance, biomarkers and haemodynamic profile in the 6-month follow-up period.
RESUMO FÁRMACOS INOTRÓPICOS E VASOPRESSORES
Doumuro Sodium restriction versus daily maintenance replacement in very low birth weight premature neonates: Relation between proton magnetic resonance spectroscopy within 18 hours of birth asphyxia and neurodevelopment at 1 year of age. Publicar un comentario Se ruega que los autores de los comentarios se identifiquen nombre, apellidos, lugar de trabajo. Glucocorticoid-responsive hypotension in extremely low birth weight newborns. The effect of hydrocortisone on blood pressure in preterm neonates with vasopressor-resistant hypotension. The effect of profound umbilical artery acidemia in term neonates admitted to a newborn nursery.
Inotrópicos y Vasopresores